Evaluation of Serum MIP-1β and MCP-2 Levels in Major Depressive Disorder: A Case-control Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Jun 18

PMID 38889138

Authors

Mariya Akter

A S M Roknuzzaman

Mohammad Shahriar

Sardar Mohammad Ashraful Islam

Mohiuddin Ahmed Bhuiyan

M M A Shalahuddin Qusar

Eva Rahman Kabir

Rabiul Islam

Affiliations

Soon will be listed here.

Abstract

Background: Major depressive disorder (MDD) is a common and debilitating mental illness characterized by persistent feelings of sadness, hopelessness, and a lack of interest in daily activities. The objective of this study was to investigate whether levels of macrophage inflammatory protein-1β (MIP-1β) and macrophage chemoattractant protein-2 (MCP-2) in the blood were associated with the pathophysiology and development of MDD compared to healthy controls (HCs).

Methods: This case-control study was conducted involving 50 MDD patients and 38 HCs. We performed a comprehensive assessment to match age, sex, BMI, and socio-demographic profile between the groups. The study excluded participants with chronic infection, inflammatory diseases, coexisting psychiatric disorder, history of liver and kidney diseases, and individuals who are under antipsychotic medications. A professional psychiatrist diagnosed MDD patients and evaluated HCs based on the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria. The severity of depression was assessed using the Hamilton Depression (Ham-D) rating scale. Commercially available enzyme-linked immunosorbent assay (ELISA) kits were used to quantify the serum MIP-1β and MCP-2 levels.

Results: The results indicated elevated serum MIP-1β levels (207.73±24.24 pg/ml) in MDD patients compared to HCs (58.77±9.14 pg/ml). This difference in concentration is positively correlated with severity of disease symptoms (r = 0.451; p<0.001). Similarly, the levels of MCP-2 were found to be elevated in patients compared to controls (143.61±19.92 vs. 56.84±4.02 pg/ml; p = 0.003), with a positive correlation with the Ham-D scores (r = 0.373; p = 0.004).

Conclusion: According to this study, elevated levels of MIP-1β and MCP-2 may be associated with the pathophysiology and development of MDD. These increased serum MIP-1β and MCP-2 levels could be used as risk assessment tools for MDD. The present findings urge further research and the development of therapeutic and diagnostic approaches for depression.

References

Sarker R, Qusar M, Islam S, Bhuiyan M, Islam M . Association of granulocyte macrophage colony-stimulating factor and interleukin-17 levels with obsessive-compulsive disorder: a case-control study findings. Sci Rep. 2023; 13(1):18976. PMC: 10624891. DOI: 10.1038/s41598-023-46401-8. View

Liu M, Tsai S, Yeh H, Wu C, Lin C . MCP-2/CCL8 Level Associated With Suicidal Ideation in Elderly Men With Major Depression. Arch Suicide Res. 2020; 24(3):467-476. DOI: 10.1080/13811118.2019.1649772. View

Leighton S, Nerurkar L, Krishnadas R, Johnman C, Graham G, Cavanagh J . Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. Mol Psychiatry. 2017; 23(1):48-58. PMC: 5754468. DOI: 10.1038/mp.2017.205. View

Leonard B . Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 48:261-7. DOI: 10.1016/j.pnpbp.2013.10.018. View

Berk M, Kohler-Forsberg O, Turner M, Penninx B, Wrobel A, Firth J . Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management. World Psychiatry. 2023; 22(3):366-387. PMC: 10503929. DOI: 10.1002/wps.21110. View

Cocchi F, Devico A, Yarchoan R, Redfield R, Cleghorn F, Blattner W . Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci U S A. 2000; 97(25):13812-7. PMC: 17658. DOI: 10.1073/pnas.240469997. View

Nayem J, Sarker R, Roknuzzaman A, Qusar M, Raihan S, Islam M . Altered serum TNF-α and MCP-4 levels are associated with the pathophysiology of major depressive disorder: A case-control study results. PLoS One. 2023; 18(11):e0294288. PMC: 10651034. DOI: 10.1371/journal.pone.0294288. View

Nahar Z, Nowshin D, Roknuzzaman A, Sohan M, Islam S, Qusar M . Serum levels of interleukin-33 and mesencephalic astrocyte derived neurotrophic factors in patients with major depressive disorder: a cross-sectional comparative design. BMC Psychiatry. 2024; 24(1):47. PMC: 10785548. DOI: 10.1186/s12888-023-05463-8. View

Salsabil L, Shahriar M, Islam S, Bhuiyan M, Qusar M, Islam M . Higher serum nerve growth factor levels are associated with major depressive disorder pathophysiology: a case-control study. J Int Med Res. 2023; 51(4):3000605231166222. PMC: 10107982. DOI: 10.1177/03000605231166222. View

10.

Sarmin N, Roknuzzaman A, Mouree T, Islam M, Al Mahmud Z . Evaluation of serum interleukin-12 and interleukin-4 as potential biomarkers for the diagnosis of major depressive disorder. Sci Rep. 2024; 14(1):1652. PMC: 10796357. DOI: 10.1038/s41598-024-51932-9. View

11.

Eyre H, Baune B . Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology. 2012; 37(9):1397-416. DOI: 10.1016/j.psyneuen.2012.03.019. View

12.

Supti K, Asaduzzaman M, Suhee F, Shahriar M, Islam S, Bhuiyan M . Elevated Serum Macrophage Migration Inhibitory Factor Levels are Associated With Major Depressive Disorder. Clin Pathol. 2023; 16:2632010X231220841. PMC: 10748934. DOI: 10.1177/2632010X231220841. View

13.

Ciechanowska A, Popiolek-Barczyk K, Pawlik K, Ciapala K, Oggioni M, Mercurio D . Changes in macrophage inflammatory protein-1 (MIP-1) family members expression induced by traumatic brain injury in mice. Immunobiology. 2020; 225(3):151911. DOI: 10.1016/j.imbio.2020.151911. View

14.

Nahar Z, Sal-Sabil N, Sohan M, Qusar M, Islam M . Higher serum interleukin-12 levels are associated with the pathophysiology of major depressive disorder: A case-control study results. Health Sci Rep. 2022; 6(1):e1005. PMC: 9789678. DOI: 10.1002/hsr2.1005. View

15.

Nishuty N, Khandoker M, Karmoker J, Ferdous S, Shahriar M, Qusar M . Evaluation of Serum Interleukin-6 and C-reactive Protein Levels in Drug-naïve Major Depressive Disorder Patients. Cureus. 2019; 11(1):e3868. PMC: 6414189. DOI: 10.7759/cureus.3868. View

16.

Daria S, Proma M, Shahriar M, Islam S, Bhuiyan M, Islam M . Serum interferon-gamma level is associated with drug-naïve major depressive disorder. SAGE Open Med. 2020; 8:2050312120974169. PMC: 7682211. DOI: 10.1177/2050312120974169. View

17.

Islam M, Sohan M, Daria S, Al Masud A, Ahmed M, Roy A . Evaluation of inflammatory cytokines in drug-naïve major depressive disorder: A systematic review and meta-analysis. Int J Immunopathol Pharmacol. 2023; 37:3946320231198828. PMC: 10467201. DOI: 10.1177/03946320231198828. View

18.

Rahman S, Shanta A, Daria S, Nahar Z, Shahriar M, Qusar M . Increased serum resistin but not G-CSF levels are associated in the pathophysiology of major depressive disorder: Findings from a case-control study. PLoS One. 2022; 17(2):e0264404. PMC: 8880862. DOI: 10.1371/journal.pone.0264404. View

19.

Das R, Emon M, Chowdhury S, Huque S, Zahan T, Islam M . Evaluation of Serum Glial Cell Line-derived Neurotrophic Factor in Bangladeshi Major Depressive Disorder Patients. Cureus. 2019; 11(11):e6081. PMC: 6894901. DOI: 10.7759/cureus.6081. View

20.

Keers R, Uher R . Gene-environment interaction in major depression and antidepressant treatment response. Curr Psychiatry Rep. 2011; 14(2):129-37. DOI: 10.1007/s11920-011-0251-x. View